et Zucc., can activate the activities of ABCA1, ABCG1, and ApoE with PGC-1α as the central target to inhibit lipid deposition in cells and improve lipid metabolism disorder in the kidney, thus preventing or delaying the occurrence and development of DN (Figure 8). Here, PPARGC1A is linked to liver dysplastic nodule.